Stay up-to-date with our latest news

Announcements

July 2, 2026

Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market
Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.
Read here

January 8, 2026

Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research
Read here

December 16, 2025

Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
Read here

December 2, 2025

Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer
Read here

March 6, 2025

Evidation Appoints Leslie Oley Wilberforce as CEO
Read here

October 3, 2024

Evidation appoints Phil Johnson as Chief Commercial Officer
Read here

September 17, 2024

Trialbee and Evidation partner to accelerate and diversify clinical research recruitment
Read here

July 15, 2024

Rock Health shares findings from weight care survey with Evidation
Read here

July 1, 2024

Frost & Sullivan awards Evidation for its direct-to-participant real world data solutions
Read here

June 20, 2024

Evidation launches MigraineSmart on the Evidation app
Read here

May 6, 2024

Evidation shares real world data on GLP-1 use and social determinants of health at ISPOR 2024
Read here

November 16, 2023

Evidation selected by Our Future Health as participant platform for UK’s largest health research program
Read here

October 17, 2023

BARDA expands partnership with Evidation to validate and improve machine learning models for early detection of influenza-like illness using wearables
Read here